Table 1 Demographic and clinical characteristics
Training cohort | Test cohort | ||
|---|---|---|---|
Characteristics | Number (%) | Number (%) | P value |
Case | 139 (100.0%) | 139 (100.0%) | |
Age (y) | 0.628 | ||
≤ 45 | 58 (41.7%) | 62 (44.6%) | |
≥ 46 | 81 (58.3%) | 77 (55.4%) | |
cT stage | 0.521 | ||
T1 | 15 (10.8%) | 11 (7.9%) | |
T2 | 83 (59.7%) | 92 (66.2%) | |
T3 | 27 (19.4%) | 20 (14.4%) | |
T4 | 14 (10.1%) | 16 (11.5%) | |
cN stage | 0.200 | ||
N0 | 19 (13.7%) | 9 (6.5%) | |
N1 | 75 (54.0%) | 76 (54.7%) | |
N2 | 27 (19.4%) | 35 (25.2%) | |
N3 | 18 (12.9%) | 19 (13.7%) | |
ypT stage | 0.360 | ||
T0 | 52 (37.4%) | 49 (35.0%) | |
T1 | 63 (45.3%) | 75 (53.6%) | |
T2 | 20 (14.4%) | 12 (8.6%) | |
T3 | 4 (1.4%) | 4 (1.4%) | |
ypT stage | 0.332 | ||
T0 | 64 (46.0%) | 53 (38.1%) | |
T1 | 36 (25.9%) | 43 (30.9%) | |
T2 | 24 (17.3%) | 32 (23.0%) | |
T3 | 15 (10.8%) | 11 (7.9%) | |
pCR | 0.887 | ||
pCR | 33 (23.7%) | 32 (23.0%) | |
Non-pCR | 106 (76.3%) | 107 (77.0%) | |
ER status | 0.708 | ||
Positive | 90 (64.7%) | 87 (62.6%) | |
Negative | 49 (35.3%) | 52 (37.4%) | |
PR status | 0.400 | ||
Positive | 77 (55.4%) | 70 (50.4%) | |
Negative | 62 (44.6%) | 69 (49.6%) | |
HER-2 status | 0.694 | ||
Positive | 96 (69.1%) | 99 (71.2%) | |
Negative | 43 (30.1%) | 40 (28.8%) | |
Adjuvant chemotherapy | 0.462 | ||
Yes | 81 (58.3%) | 87 (62.6%) | |
No | 58 (41.7%) | 52 (37.4%) | |
IMNI | 0.407 | ||
Yes | 32 (23.0%) | 38 (27.3%) | |
No | 107 (77.0%) | 101 (72.7%) | |
Anti-HER2 therapy | 0.971 | ||
Yes | 11 (15.7%) | 11 (15.9%) | |
No | 59 (84.3%) | 58 (84.1%) | |
Hormonal therapy | 0.622 | ||
Yes | 32 (23.0%) | 32 (23.0%) | |
No | 102 (73.4%) | 105 (75.5%) | |
Unknown | 5 (3.6%) | 2 (1.4%) |